Atopic Dermatitis Clinical Trials

Find Atopic Dermatitis Clinical Trials Near You

Evaluation of a Non-Invasive Device for Early Detection of Flares in Adults and Adolescents With Atopic Dermatitis

Status: Recruiting
Location: See all (4) locations...
Intervention Type: Device
Study Type: Observational
SUMMARY

This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device. Participants aged 12 to 89 years with a history of AD flares will use the device at home for about 90 days. Participants will complete device measurements, electronic diary entries, and up to five in-person study visits. The study is based on the idea that changes in skin barrier function may occur before an AD flare becomes visible or symptoms begin. Information collected during the study, including device measurements, diary entries, and investigator assessments, will be used to evaluate whether these changes may help estimate the likelihood of an AD flare before visible signs or symptoms occur.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 12
Maximum Age: 89
Healthy Volunteers: f
View:

⁃ Participants may be eligible if they:

• Are 12 to 89 years old.

• Have been diagnosed with atopic dermatitis (eczema).

• Have had at least one atopic dermatitis flare within the past 2 months.

• Are willing and able to use the Nevisense Go device at home, complete an electronic symptom diary, and attend study visits.

• If currently using systemic treatment for atopic dermatitis, have been on the same treatment for at least 3 months and do not plan to change treatment during the study.

Locations
United States
Arizona
U.S. Dermatology Partners
RECRUITING
Phoenix
New Hampshire
StracSkin, PLLC
RECRUITING
Portsmouth
Nevada
Las Vegas Dermatology
RECRUITING
Las Vegas
Texas
Harrison Institute for Clinical Research
RECRUITING
Missouri City
Contact Information
Primary
Clare Johnson E VP Clinical Research
cjohnson@castlebiosciences.com
602-499-0301
Time Frame
Start Date: 2026-05-29
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 450
Related Therapeutic Areas
Sponsors
Leads: Castle Biosciences Incorporated
Collaborators: SciBase AB

This content was sourced from clinicaltrials.gov